My vague recollection of that Roche conference call stated they expected top line results in 2nd half 2014 and launch in 2015. Roche stated they would eventually try to update on clinicaltrials.gov site. I will post again after I listen to the call again.Briefly mentioned in Q&A. It was said that clinicaltrials.gov site has an error with completion date of 2017. Roche said it would be corrected and certainly sooner than that. I probably got my timeline specifics from this link. http://seekingalpha.com/article/901801-exelixis-first-partne...Short timelines - The phase III trial will start next month with progression-free survival as the primary endpoint. Enrollment should be very quick, given Roche's experience in the indication (Zelboraf was the 1st approved drug for BRAF-mutated melanoma) and the fact that melanoma patients are routinely screened for BRAF status and treated with Zelboraf. Top line results could be available in mid-2014, and Roche expects to submit the combination for approval in 2014.Don't know where Ohad got his timeline info. Maybe an educated guess?
Best Of |
Favorites & Replies |
Start a New Board |
My Fool |
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ra